DAMORA THERAPEUTICS, INC. Capital Expenditures
DAMORA THERAPEUTICS, INC. (DMRA) reported Capital Expenditures of $196.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-08.
Discontinued › Cash Flow
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2024-03-08
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $41.00K.
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $138.00K, a 193.62% increase year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was -$26.00K, a 122.61% decline year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $43.00K, a 33.85% decline year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $196.00K, a 12.11% decline from fiscal 2021.
- DAMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $223.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2022-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $179.00K derived: sum of 2 quarters · filed 2024-03-08 | $153.00K derived: sum of 3 quarters · filed 2024-03-08 | $196.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $112.00K derived: sum of 2 quarters · filed 2023-11-06 | $155.00K 10-Q · filed 2023-11-06 | $151.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $17.00K 10-Q · filed 2023-07-31 | $13.00K derived: sum of 3 quarters · filed 2023-07-31 | $60.00K derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $43.00K 10-Q · filed 2023-04-28 | $39.00K derived: sum of 2 quarters · filed 2023-04-28 | $86.00K derived: sum of 3 quarters · filed 2023-04-28 | $201.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $43.00K derived: sum of 2 quarters · filed 2023-03-09 | $158.00K derived: sum of 3 quarters · filed 2023-03-09 | $223.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $162.00K derived: sum of 2 quarters · filed 2022-11-08 | $227.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $180.00K 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $65.00K 10-Q · filed 2022-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |